We previously showed that an inflammation-related, molecule leucine-rich alpha-2 glycoprotein (LRG) enhances the transforming growth factor (TGF)-β1-induced phosphorylation of Smad proteins and is elevated in patients with pancreatic ductal adenocarcinoma (PDAC). As TGF-β/Smad signaling is considered to play a key role in epithelial-mesenchymal transition (EMT), we attempted to clarify the mechanism underlying LRG-related EMT in relation to metastasis in PDAC. We cultured LRG- tion. In the plasma LRG-high group, the recurrence rate tended to be higher and the recurrence-free survival (RFS) tended to be worse in comparison with the plasma LRG-low group. LRG enhanced EMT induced by TGF-β signaling, thus indicating that LRG has a significant effect on the metastasis of PDAC.
5-year OS rate after curative resection without adjuvant chemotherapy was only 10% in the CONKO study. 5 However, in the JASPAC study, which noted that the survival time of resectable PDAC patients was longer in comparison with patients with unresectable PDAC, the 5-year OS rate was approximately 40% after R0 resection with S-1 adjuvant chemotherapy. 6 Accordingly, we have begun performing neo-adjuvant chemoradiation therapy at our institution, which may improve the OS [7] [8] [9] [10] ; however, the risk of liver metastasis remains, even with good control of local extension, especially in borderline resectable cases of PDAC. 11 We previously showed that the existence of PDAC was related to inflammation-related molecules. 12 During our studies on cancer and inflammation, we searched for new inflammation-related molecules induced by interleukin (IL)-6 (other than C-reactive proteins) using a quantitative proteomic approach 13 and identified leucinerich alpha-2-glycoprotein (LRG). LRG, which was first purified from human serum, 14, 15 is an inflammatory acute-phase glycoprotein that mainly exists in the liver and neutrophils. 16, 17 Its production is induced by several inflammatory cytokines, including, but not limited to, IL-1, IL-6 and IL-22, and it has been shown to generate transforming growth factor (TGF)-β1-related angiogenesis in non-cancerous regions. 18 In addition, we and others have reported that several cancers produce IL-6 (eg, biliary tract cancer [BTC] 11, 19 ). The levels of serum LRG (considered here as secretory LRG) in PDAC patients were found to be elevated in comparison with healthy volunteers, 12 as well as in cancerous regions without cancer-related inflammation. 12 We therefore hypothesized that the levels of inflammatory cytokines are also elevated in PDAC, thereby inducing LRG production. In addition, LRG was shown to induce the TGF-related phosphorylation of smad2 in cancer. 20 Transforming growth factor (TGF)-β/Smad signaling is considered to play a key role in epithelial-mesenchymal transition (EMT), which can cause metastasis, invasion and/or chemoresistance. We therefore hypothesized that because LRG levels increase with PDAC progression, 12 LRG induces TGF-related smad2 phosphorylation, 20 which results in early distant metastasis, even in cases of R0 resection. 11 PDAC-related LRG elevation may, therefore, induce distant metastasis via TGF-β1-related EMT with Smad phosphorylation.
In the present study, we aimed to clarify the mechanism underlying LRG-related EMT-induced metastasis in PDAC. We evaluated the relationship of LRG and other inflammatory cytokines in PDAC cells with TGF-β-inducing EMT. We also examined the mechanism underlying TGF-β-related EMT via Smad phosphorylation. Our data not only showed that the LRG levels could be used to predict metastasis but also suggested the utility of this molecule as a therapeutic target. FBS (Serum Source International, Charlotte, NC, USA) and 100 U/mL penicillin and 100 μg/mL streptomycin (Nacalai Tesque). The cultures were maintained at 37°C in a humidified atmosphere at 5% CO 2 .
| MATERIAL S AND ME THODS

| Cell lines
| Recombinant proteins
Recombinant human TGF-β1 and IL-1β, tumor necrosis factor (TNF)-α, IL-6 and IL-22 were purchased from PeproTech (Rocky Hill, NJ, USA). Recombinant human LRG was purchased from R&D (Minneapolis, MN, USA).
| Patients and sample collection
Peripheral blood plasma samples were obtained just before and after surgery from 39 patients with PDAC who underwent R0 resection [UICC]) criteria were used for surgical and pathological staging and to categorize the histologic differentiation.
| Ethics approval
Informed consent was obtained from all patients, and all studies involving human subjects were approved by the Ethical Committee of the Osaka University Hospital (IRB# 17308).
| Quantification of plasma leucine-rich alpha-2 glycoprotein (ELISA)
The plasma LRG levels were determined using an ELISA, as previously described. 
| Immunohistochemical staining
Sections were prepared from the abovementioned resected specimens (4 μm). Immunohistochemical (IHC) staining for LRG was performed using a rabbit anti-LRG monoclonal antibody 
| Real-time RT-PCR
Total RNA was isolated from the indicated cells using an RNeasy Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocol. 
| Western blotting
| Generation of cell lines with the stable expression of human leucine-rich alpha-2-glycoprotein
To generate cell lines with the stable expression of human LRG (hLRG), Panc1 cells with a TGF-β1 receptor were transfected with the pcDNA3.1 LRG expression vector, as described previously. 20 Transfected cells were selected using 1000 μg/mL of geneticin (Invitrogen, Carlsbad, CA, USA). Clones were maintained in 250 μg/mL of geneticin to ensure the stability of the expression.
| siRNA transfection
siRNA treatment was performed with Dharmacon ON-TARGETplus The cells were transfected with siRNA using Lipofectamine 2000
Reagent (Invitrogen) according to the manufacturer's instructions.
| Immunocytochemistry
Panc1 cells were grown on coverslips and fixed with PBS (pH 7. 
| Invasion assays
Invasion assays were performed with invasion chambers loaded with Matrigel, according to the manufacturer's instructions (Biocoat Matrigel Invasion Chamber; Collaborative Biomedical Products; Becton Dickinson), as described previously. 22 In brief, 5 × 10 4 cells were overlaid onto the Matrigel matrix on a membrane with 8-μm pores (upper chamber: FBS .5%, lower chamber: FBS 10%). After 48 hours, the cells that had invaded the undersurface of the membrane were fixed with methanol and stained with thiazine and eosinate. Five microscopic fields were randomly selected for cell counting.
| Cell viability assays
Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2 ,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) assay, as described previously. 23 Each cell line was seeded onto a 96-well plate (3 × 10 3 cells/well) and incubated for 48 and 72 hours. Cell viability was then evaluated based on the absorbance using MTT solution.
| Statistical analyses
Statistical analyses were performed using the JMP Pro 13.2.1 software program (SAS Institute, Cary, NC, USA). The OS, recurrencefree survival (RFS), and cumulative distant metastasis rates were evaluated using the Kaplan-Meier method and assessed using the log-rank test. All parameters found to be significant in univariate analyses using the Cox proportional hazard model were included in a multivariate survival analysis. Unpaired Student's t tests were performed to test the significance of differences between 2 groups.
P-values of <.05 were considered to indicate statistical significance.
| RE SULTS
| Selection of pancreatic ductal adenocarcinoma cell lines
We evaluated 5 pancreatic cancer cell lines (AsPC-1, BxPC-3, MiaPACA2, Suit2 and Panc1) and ultimately selected the Panc1 cell line because it expresses EMT markers with wild Smad4. EMT is reportedly induced in BxPC3 and MiaPACA cells by TGF-β. 24 We confirmed the expression of EMT markers (E-cadherin, N-cadherin and Figure S3A ) and N-cadherin proteins ( Figure   S3C ), while the expression of E-cadherin was unaffected ( Figure   S3B ). To investigate the role of LRG in PDAC cells, we constructed continuous LRG-expressing Panc1 cells (Figure 2A) , as Panc1 cells contain a TGF-β receptor. 26 We constructed 9 cell clones that stably expressed LRG (Panc1/LRG, Figure S4 ) and ultimately selected clone #2 (although we initially selected clones #1 and #2 because of their high LRG production). To investigate EMT, we evaluated the changes in the E-cadherin expression of these clones on exposure to TGF-β1 ( Figure S5 E-cadherin protein) . Panc1/LRG clone #2 showed the most remarkable change in the expression of Ecadherin. We therefore selected Panc1/LRG clone #2 for further experiments.
The morphology of the LRG-expressing Panc1 (Panc1/LRG) cells was similar to that of the Panc1 parent cells without any stimulation.
A spindle-like shape was visualized more often than other shapes in Panc1/LRG with TGF-β1 exposure ( Figure 2B) . Furthermore, the expression of E-cadherin decreased while that of vimentin increased after TGF-β1 exposure in Panc1/LRG than in parental Panc1 cells ( Figure 2C ). We confirmed the changes in the E-cadherin levels by immunocytochemistry, and a greater decrease in the E-cadherin expression was observed in Panc1/LRG cells exposed to TGF-β1 in comparison with parental Panc1 and Panc1/pcDNA cells ( Figure 2D ).
In contrast, the knockdown of LRG by siRNA (siLRG) resulted in the elevation of E-cadherin ( Figure S6A,B) . In an invasion assay, Panc1/ LRG cells showed a greater invasion ability than the parental Panc1 
| Survival of pancreatic ductal adenocarcinoma patients after R0 resection and their leucine-rich alpha-2 glycoprotein expression
We examined the preoperative plasma LRG values of PDAC patients (39 cases). The recurrence rate tended to be higher and the RFS was worse in patients with high plasma levels of LRG than in patients with low plasma levels of LRG ( Figure 5A-D) , with no marked difference in the baseline characteristics of the patients in these 2 groups (Table 1 ). In the group without preoperative chemoradiation therapy (22 cases), both the recurrence rate and the distant recurrence rate were significantly increased ( Figure 5E -H), with no marked difference in the baseline characteristics of the patients in the 2 groups (Table 2 ). However, in the group with preoperative chemoradiation therapy, there were no marked differences in the recurrence rate or the distant recurrence rate (Figure 5I-L) . Regarding immunohistochemical staining for LRG, the median RFS in patients who were strongly positive for LRG was shorter than that in patients who were weakly positive for LRG (.53 years vs 1.04 years) among the patients without preoperative chemoradiation therapy.
Taken together, these findings suggest that the production of LRG in plasma influenced the development of distant metastasis in patients with PDAC.
We confirmed the immunoreactivity for LRG, Smad4, pSmad2, Ecadherin and vimentin in resected PDAC specimens ( Figure S8A -E).
LRG was strongly stained in 12 cases (34%, Figure S8A ), and Smad4 mutations were noted in 15 cases (43%) in our study ( Figure S8B ).
Among the specimens with wild-type (20 cases) Smad4, pSmad2
was strongly stained in 10 cases (50%, Figure S8C ), E-cadherin was weakly stained in 4 cases (20%, Figure S8D ), and vimentin was strongly stained in 13 cases (65%, Figure S8E ). We examined the IHC staining for LRG and pSmad2, and evaluated any differences Figure S8H ). In contrast, among the specimens with a Smad4 mutation, LRG was not relevant for either E-cadherin or pSmad2 ( Figure S8I ).
Leucine-rich alpha-2-glycoprotein is produced not only by PDAC cells but also by hepatocytes. 17 Thus, we also calculated the rate of decrease in the LRG expression after surgery. We only examined the LRG produced by PDAC cells and excluded any LRG produced by hepatocytes. We measured the plasma LRG levels in PDAC patients before and after surgery ( Figure S9A ). In most patients, the plasma LRG level was decreased after surgery ( Figure S9B ). We confirmed the immunoreactivity for LRG in the resected specimen ( Figure S8A ).
Strong positivity for LRG was detected in the patients with high plasma levels of LRG ( Figure S9C ).
| D ISCUSS I ON
As hypothesized, we found that the production LRG by PDAC cells was induced by stimulation with inflammatory cytokines.
Furthermore, the EMT and invasion induced by TGF-β1 were enforced by LRG, suggesting a possible mechanism underlying the relationship between LRG and distant metastasis. We and other groups have previously shown that LRG binds to TGF-β1 and/or its receptors and modulates the downstream pathways of TGF-β F I G U R E 5 Recurrence pattern analyses in pancreatic cancer patients according to the plasma leucine-rich alpha-2-glycoprotein (LRG) levels in patients treated with or without chemoradiation. A-D, Total, local and distant recurrence according to the preoperative plasma LRG level (A) and the recurrence-free survival (RFS) curves for total (B), local (C) and distant recurrence (D). E, F, D and H, Recurrence pattern without preoperative chemoradiation (E) and the RFS curves for total (F), local (G) and distant recurrence (H). I-L, Recurrence pattern with preoperative chemoradiation (I) and the RFS curves for total (J), local (K) and distant recurrence (L) signaling in a Smad1/5-depedent 18, 27 or Smad2-dependent 20 manner. Wang et al 18 showed that endoglin plays a critical role in the switch of TGF-β signaling from the Smad2 to the Smad1/5 pathway.
Interestingly, we previously showed that LRG binds to TGF-β1 and enhances the Smad2 pathway in an endoglin-independent manner. 20, 28 Together with the findings of these previous reports, the results of this study suggest that LRG in association with TGF-β1
enhances the TGF-β-induced EMT via Smad2 signals and increases the expression of the TGF-β type I receptor, which seems to be associated with increased EMT in TGF-β1-sensitive PDAC cells.
Inflammatory change has not been directly seen in PDAC; however, several reports have suggested that inflammatory cytokines may affect the progression of PDAC, 12,29-37 especially IL-6. These cytokines also affect the progression of other cancers. 38 For example, BTC, a counterpart of PDAC, is commonly studied in this field, and we previously showed that inflammatory cytokines enhance resistance to apoptosis 39, 40 and the Smad4 regulation of cancer development 41 via the crosstalk between IL-6 and TGF-β1 in this entity. 42 In PDAC cells, it was reported that IL-6 was involved in EMT via stat3
37
; however, these studies only showed an "indirect effect"
on EMT, including a missing link between IL-6 signaling and EMT.
Our study directly showed that inflammatory cytokines (IL-6) induced the secretion of LRG and that the secreted LRG subsequently increased the TGF-related EMT. We therefore consider LRG to be a missing link between inflammation and EMT.
It was reported that LRG was an approximately 50-kDa glycoprotein that contains repetitive sequences with a leucine-rich motif. 14 Positive for microinvasion lymphatic system 65% 68% 1.0000
Positive for microinvasion to venous system 25% 42%
Positive for microinvasion to nervous system 90% 89%
Values are expressed as mean ± SD or number (%). LRG, leucine-rich alpha-2-glycoprotein; N/A, not applicable; UICC, Union for International Cancer Control.
TA B L E 1 Patients' characteristics regarding plasma LRG directly induce EMT during inflammation as well as act as a marker of inflammation.
Our data showed that cytokines induced the production of LRG in PDAC cells. We and others have studied the expression of LRG by several cells. The LRG expression without stimulation was found to be very low in normal cells and slightly high in the liver, 20 while the expression was elevated in gastric cancer cells. 48 In the present study, the LRG expression in PDAC was much lower than that in HCC cells. The induction of LRG elevation by cytokines has not been well investigated, and the levels in primary bronchial epithelial cells were only elevated by IL-4 and TNF-α. 49 We showed that the LRG expression and production were increased in a dosedependent manner by exposure to several cytokines, including making it not only a good marker (a marker of progression and for judging the effect of therapy) but also a useful therapeutic target for regulating EMT. Smad4 mutations should also be noted, as 20%-50%
of PDAC have a Smad4 mutation. EMT may be induced by different pathways depending on the presence of a Smad4 mutation. For wild-type Smad4, TGF-β1 regulates tumor progression by a tumor cell-autonomous mechanism, 50 as shown in our in vitro study using wild-type Smad4 PDAC cells. In contrast, for mutant Smad4, TGF-β reportedly induces EMT not via Smad but by an alternative pathway (eg, the Ras-MEK-ERK-pathway). 26 Our in vitro data indicated that LRG enhances TGF-β-mediated EMT in wild-type Smad4 PDAC cells, and these findings are supported by our data using resected specimens ( Figure S9C ).
In conclusion, LRG enhances TGF-β, inducing EMT, which is associated with distant metastasis in PDAC. LRG may be useful as a universal marker of tumor progression and a potential therapeutic target for regulating EMT. 
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